AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02703519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of uterine scar tissue
Description: resection of uterine scar tissue of a previous cesarean section during a second cesarean section
Study NCT01776749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SubQ
Description: Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
Study NCT01776749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SubQ
Description: Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
Study NCT01077167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
Study NCT03497000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCTA-guided Photodynamic therapy
Description: Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
Study NCT03497000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICGA-guided Photodynamic therapy
Description: Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
Study NCT02484131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials/mail
Description: Participants in this group will receive any educational materials by mail during hte follow-up period.
Study NCT02484131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials/participant choice
Description: Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
Study NCT03381807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAESCs
Description: 5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
Study NCT00976859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Modification
Description: Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
Study NCT00976859 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Waitlist control group
Description: Patients in the wait list control group are treated after a waiting period of five weeks
Study NCT04242901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
Description: Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
Study NCT01260194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
Study NCT00708656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalazine (Asacol®)
Description: 800 mg tablets
Study NCT00708656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalazine (Asacol®)
Description: 800 mg tablets
Study NCT02103478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 Dose Escalation
Description: Oral investigational product and approved IV decitabine
Study NCT02103478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 Dose Confirmation
Description: Randomization cross over design for courses 1 and 2
Study NCT02103478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 Fixed-Dose Combination
Description: Fixed-dose investigational product
Study NCT04993339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OOC
Description: The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
Study NCT03074721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PCI Suite Software
Description: PCI with PCI Suite Software
Study NCT03074721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional PCI
Description: conventional PCI without PCI Software
Study NCT00125827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine (oral formulation)
Description: Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
Study NCT05029167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive PaO2
Description: Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
Study NCT05029167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
Study NCT05029167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal PaO2
Description: Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
Study NCT05029167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Study NCT02008955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine intake provided as a milkshake
Description: There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
Study NCT03842202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
Study NCT03842202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once weekly injections of semaglutide matched placebo.
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium Animalis Oral Product
Description: The synbiotic group will receive this product.
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin Oral Tablet
Description: 50mg/kg/day B.I.D.
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Oral Tablet
Description: 50mg/kg/day B.I.D.
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clarithromycin Oral Tablet
Description: 15 mg/kg/day B.I.D.
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Oral Tablet
Description: 15 mg/kg/day B.I.D.
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: 1 mg/kg/day
Study NCT03165253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 1 mg/kg/day
Study NCT02134431 — intervention group
Intervention type: DEVICE
Intervention: flexible sigmoidoscopy or colonoscopy with biopsies
Description: Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
Study NCT02289599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307
Study NCT03536728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
Study NCT03536728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
Study NCT01540370 — intervention group
Intervention type: OTHER
Intervention: No Treatment
Description: No treatment
Study NCT01412840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diclofenac and sterile water injections
Description: The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
Study NCT01412840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac and isotonic saline
Description: The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
Study NCT02566759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.
Study NCT02566759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.
Study NCT04839835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: waiting room enriched with music, paintings and artificial plants
Description: waiting room enriched with music, paintings and artificial plants
Study NCT03862807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran was administered via IV infusion.
Study NCT00558831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide
Description: Benzoyl Peroxide 2.5%
Study NCT00558831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing Lotion
Study NCT01915485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lu 177
Description: Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
Study NCT03840473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
Study NCT03840473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT
Description: The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
Study NCT03840473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intervention
Description: Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
Study NCT03840473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Intervention
Description: Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
Study NCT04189666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine Transdermal System [Exelon]
Description: compare the ability of the drug in preventing postoperative delirium
Study NCT04189666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: compare the ability of the drug in preventing postoperative delirium
Study NCT04051658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study NCT04051658 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study NCT04471766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Certified cloth face mask plus preventive information
Description: Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents > 10 years old
Study NCT04471766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive information
Description: Advice on how to prevent COVID-19 according to the government´ policy
Study NCT04471766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preventive information
Description: Advice on how to prevent COVID-19 according to the government´ policy
Study NCT01934062 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~--------------------------------------------------------------------------------
Study NCT04376073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
Study NCT04376073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
Study NCT03777800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body therapy
Description: Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session.
Study NCT03777800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard treatment
Study NCT00903409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Description: Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study NCT02850783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 89Zr-nanocoll and Indocyanine Green
Study NCT01124500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate via transdermal patch compared to placebo
Description: The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
Study NCT01281176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01281176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01281176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01281176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01281176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02072707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial VT ablation
Description: Combined Epicardial and Endocardial VT Ablation
Study NCT02072707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial VT Ablation
Description: Endocardial Only VT ablation
Study NCT03824483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: zanubrutinib (160mg by mouth BID)
Study NCT03824483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter).
Study NCT03824483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
Study NCT01915498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Study NCT02159651 — intervention group
Intervention type: DRUG
Intervention: tacrolimus
Description: oral
Study NCT01711814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT04212624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human retinal pigment epithelial (HuRPE) cell injection
Description: Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
Study NCT02566759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet
Description: TAK-831 tablet.
Study NCT02247310 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon®, BAY 86-5046)
Description: Patients will be treated with Betaferon
Study NCT02247310 — intervention group
Intervention type: DEVICE
Intervention: BETACONNECT
Description: Auto-injector device to support the injection of Betaferon
Study NCT04330079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg once daily for 6 months.